 ft 07 92 intern compani news chiron win fda approv kidney cancer drug  chiron biotechnolog compani receiv approv food drug administr market interleukin 2 long await treatment aggress kidney cancer approv mark end year struggl bring market wide regard promis product biotechnolog industri interleukin 2 sold brand proleukin develop cetus biotechnolog concern acquir chiron year long expens approv process drain cetus resourc proleukin har power bodi immun system attack cancer cell origin hail breakthrough cancer therapi clinic trial drug found benefit minor patient sever side effect proleukin shrank tumor 15 cent patient 4 cent achiev complet remiss 4 cent die side effect drug trial result patient receiv convent chemotherapi treatment 5 cent surviv chiron share price rose sharpli monday gain dollar 6 1 2 close dollar 48 1 4 anticip approv chiron stock fell dollar 5 8 dollar 46 5 8 close trade yesterday 